このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts

2026年9月26日 更新者:Silvana Saeed Shawky、Assiut University

This clinical trial aims to compare the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of plantar warts.

調査の概要

詳細な説明

Viral warts represent benign epidermal proliferations associated with human papillomavirus (HPV) infection. HPV is a double-stranded DNA virus with more than 150 identified types, several of which have a predilection for cutaneous tissues and can produce distinct clinical forms of warts. Transmission occurs through direct skin-to-skin contact, indirect contact with contaminated surfaces, or autoinoculation, as when a wart is scratched or picked and virus is carried to a new site.

Cutaneous warts occur worldwide, with an estimated overall population prevalence of roughly 10%, rising to 10-20% among school-aged children. Although warts may develop at any age, incidence climbs through childhood and peaks between 12 and 16 years. Most lesions are asymptomatic, but they are not without consequence: warts can produce cosmetic disfigurement and psychosocial distress, and those on weight-bearing surfaces such as the plantar skin can become painful with walking or pressure. The principal clinical types are common, plantar, plane, filiform, and genital warts.

Plantar warts, the focus of the present study, arise on the sole and are most commonly attributed to HPV types 1, 2, 4, 27 and 57. Because of the constant pressure exerted by weight-bearing, these lesions tend to grow inward rather than outward and are often covered by a thick overlying callus that can mask the lesion and delay diagnosis; adjacent warts may also coalesce into a mosaic pattern. Unlike many other cutaneous warts, plantar warts are frequently symptomatic, producing a sharp, well-localized pain on walking or standing that can meaningfully impair mobility and daily activities. Clinically, they are distinguished from corns and calluses by the presence of pinpoint black dots, corresponding to thrombosed dermal capillaries, and by interruption of the normal skin lines across the lesion.

Several therapeutic modalities are available for cutaneous warts, including destructive methods such as salicylic acid, cryotherapy, silver nitrate, electrosurgery and pulsed-dye laser, antiproliferative agents such as formaldehyde, vitamin D3, bleomycin, 5-fluorouracil, podophyllin and podophyllotoxin, topical immunological agents such as imiquimod ; However, treatment remains challenging because of variable efficacy, prolonged treatment courses, recurrence and adverse effects. No single treatment option is considered gold standard.

Intralesional therapies are an emerging and effective approach for treating recalcitrant warts. Several immunotherapeutic agents for warts including vitamin D3; tuberculin purified protein derivative (PPD); Candida antigen (Candida); the measles, mumps, rubella (MMR) vaccine, BCG, zinc sulphate and antivirals such as acyclovir have demonstrated variable complete response rates in randomized controlled trials. Unlike various other treatment options, immunotherapeutic approaches upregulate the immune system to recognize and destroy the lesions at both the target site and distant locations.

Acyclovir, a synthetic purine nucleoside analogue, is active against herpes simplex virus (HSV) and varicella-zoster virus (VZV) through a selective activation pathway: viral thymidine kinase first converts the drug to its monophosphate form, after which host-cell enzymes complete its conversion to the active triphosphate metabolite. This triphosphate form competitively blocks viral DNA polymerase and, once incorporated into the elongating viral DNA strand, halts further chain extension, thereby arresting viral DNA synthesis.

Acyclovir is considered an evolving treatment option for warts; however, its mechanism of action against HPV is not fully understood. In a recent randomized controlled trial, intralesional acyclovir (70 mg/ml) was injected at a dose of 0.1 ml using an insulin syringe into each of the largest three warts (total 0.3 ml per session), repeated every 2 weeks until complete clearance or for a maximum of five sessions, resulting in a complete response rate of 37.5%.

The therapeutic effect of zinc sulphate in warts is thought to reflect a combination of direct local cytotoxicity and immune stimulation. Following intralesional injection, it triggers a localized inflammatory cascade in which eosinophils arrive first, followed sequentially by lymphocytes and fibroblasts, which may help drive immune-mediated clearance of HPV-infected keratinocytes. Zinc also contributes to immune regulation by supporting leukocyte and natural killer cell function. However, the precise mechanism by which intralesional zinc sulphate promotes HPV clearance remains incompletely understood.

Zinc sulfate has been investigated as an effective intralesional immunotherapy treatment for warts. A recent randomized controlled study evaluated intralesional 2% zinc sulphate in patients with common, plantar, and plane warts. Zinc sulphate was prepared by dissolving 2 g in 100 ml sterile distilled water and autoclaving at 95°C for 20 minutes. A dose of 0.1 ml was injected into the largest wart until blanching or bleb formation, with treatment repeated for up to six sessions. Complete response was achieved in 68.6% of patients, while complete clearance of the target wart was observed in 74.3% of cases.

Although both agents have demonstrated promising efficacy in the treatment of cutaneous warts, so far, there is no direct comparative study evaluating intralesional acyclovir versus intralesional zinc sulphate. Therefore, the present study aims to provide a direct head to head comparison of the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of patients with plantar warts.

研究の種類

介入

入学 (推定)

76

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~50年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients aged 18-50 years of both sexes clinically diagnosed with multiple plantar warts.

Exclusion Criteria:

  • Patients with wart types other than plantar warts (genital, common, and plane warts).
  • Pregnant or lactating women.
  • Immunocompromised patients.
  • Individuals receiving systemic immunosuppressive or antiviral therapy.
  • History of hypersensitivity to acyclovir or zinc compounds.
  • Patients with current acute febrile illness or any bacterial infection.
  • Receiving any treatment for warts within 1 month before the study.
  • Concurrent other skin disorders.
  • Patients with systemic diseases (liver or renal disease, bleeding disorders).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Intralesional Acyclovir

This group will receive intralesional acyclovir

Intralesional injection of acyclovir, prepared using 250 mg acyclovir vial diluted with 3.5 ml saline (yielding an acyclovir concentration of approximately 70 mg/ml), at a dose of (0.1- 0.3 ml) injected into the largest (target) wart under aseptic precautions using an insulin syringe.

The injection will be repeated every 2 weeks until complete clearance of warts or for a maximum of five sessions.

アクティブコンパレータ:Intralesional Zinc Sulphate

This group will receive intralesional zinc sulphate 2%

Intralesional injection of 2% zinc sulphate prepared using 2 gm of zinc sulphate powder dissolved in 100 ml of sterile distilled water and autoclaved at 95°C for 20 minutes, at a dose of (0.1- 0.3 ml) in the base of the largest (target) wart .

The wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis.

Injections will be repeated for all patients into the same lesion every 2 weeks until complete clearance of warts or for a maximum of five sessions.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Clinical Response of the Injected Warts
時間枠:8 weeks

Clinical response assessed by standardized digital photographs and dermoscopic evaluation. Response will be graded using scoring system :

Score 0: neither clinical nor dermoscopic response. Score 1: clinical improvement without dermoscopic clearance. Score 2: clinical disappearance with dermoscopic evidence of residual wart tissue.

Score 3: complete clinical and dermoscopic clearance with return of normal skin markings.

8 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Dalia A Attallah, Professor、Dermatology Department Assiut University Hospital, Assiut, Egypt
  • スタディディレクター:Radwa M Bakr, Assistant Professor、Dermatology Department Assiut University Hospital, Assiut, Egypt

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2027年10月1日

研究の完了 (推定)

2028年3月1日

試験登録日

最初に提出

2026年9月18日

QC基準を満たした最初の提出物

2026年9月26日

最初の投稿 (実際)

2026年9月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月26日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する